TABLE 1.
Demographic summary of the patients included in the population pharmacokinetic model development
| Dose (mg/kg) of gatifloxacin (no. of children) | Mean value (% CV) by patient characteristica
|
No. of subjects (%)
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
| By gender
|
By race
|
||||||||
| Wt (kg) | Age (yr) | CLCR (ml/min/1.73 m2) | BSA (m2) | Male | Female | White | Black | Other | |
| 5 (22) | 28.2 (63.9) | 7.37 (70.2) | 165 (20.0) | 0.97 (45.3) | 16 (72.7) | 6 (27.3) | 12 (54.5) | 7 (31.8) | 3 (13.6) |
| 10 (33) | 28.3 (69.6) | 7.17 (75.2) | 154 (28.9) | 0.96 (49.6) | 18 (54.5) | 15 (45.5) | 17 (51.5) | 11 (33.3) | 5 (15.2) |
| 15 (27) | 26.8 (68.5) | 6.36 (74.1) | 141 (26.8) | 0.92 (45.5) | 18 (66.7) | 9 (33.3) | 16 (59.3) | 9 (33.3) | 2 (7.41) |
| All doses combined (82) | 27.8 (67.0) | 6.96 (72.9) | 153 (26.3) | 0.95 (46.7) | 52 (63.4) | 30 (36.6) | 45 (54.9) | 27 (32.9) | 10 (12.2) |
a
CV, coefficient of variation; CLCR, creatinine clearance.